- Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam
- Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe
- Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative
- Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Gender Policy Council
- Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update
- Femasys Expands Commercial Management Team with Addition of Experienced New Hires
- Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives
- Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update
- Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape
- Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
More ▼
Key statistics
On Friday, Femasys Inc (FEMY:NAQ) closed at 1.11, 347.76% above the 52 week low of 0.2479 set on Sep 18, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.08 |
---|---|
High | 1.11 |
Low | 1.08 |
Bid | 1.08 |
Offer | 1.14 |
Previous close | 1.10 |
Average volume | 159.30k |
---|---|
Shares outstanding | 22.22m |
Free float | 20.53m |
P/E (TTM) | -- |
Market cap | 24.44m USD |
EPS (TTM) | -0.8567 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 20:59 BST.
More ▼